HealthDay 
(7/4, Gordon) reported, "Taking pioglitazone (brand name Actos) raised
the risk of bladder cancer by about one-fifth, according to a new analysis " of ten studies published online July 3 in the Canadian Medical Association Journal.
(7/4, Gordon) reported, "Taking pioglitazone (brand name Actos) raised
the risk of bladder cancer by about one-fifth, according to a new analysis " of ten studies published online July 3 in the Canadian Medical Association Journal.
"Any use of a thiazolidinedione was associated with a nonsignificant 45%
higher risk in the pooled randomized trials and a significant 15%
elevated risk across the observational studies," MedPage Today
(6/4, Phend) reported. "Pioglitazone users had pooled risk ratios
ranging from 1.22 to 4.30," researchers reported. The article also
pointed out that in 2011, the Food and Drug Administration "warned...of a
further increase in bladder cancer risk with pioglitazone, now
reflected in the drug's product label."
(6/4, Phend) reported. "Pioglitazone users had pooled risk ratios
ranging from 1.22 to 4.30," researchers reported. The article also
pointed out that in 2011, the Food and Drug Administration "warned...of a
further increase in bladder cancer risk with pioglitazone, now
reflected in the drug's product label."
No comments:
Post a Comment